Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach-Reference-Cited by-同舟云学术

Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach

Published:2023-01-18 Issue:2 Volume:86 Page:264-275
ISSN:0163-3864
Container-title:Journal of Natural Products
language:en
Short-container-title:J. Nat. Prod.

Author:

Wasilewicz Andreas¹²,Kirchweger Benjamin¹^ORCID,Bojkova Denisa³,Abi Saad Marie Jose¹²,Langeder Julia¹²,Bütikofer Matthias⁴,Adelsberger Sigrid¹²^ORCID,Grienke Ulrike¹^ORCID,Cinatl Jr. Jindrich³,Petermann Olivier⁵⁶,Scapozza Leonardo⁵⁶,Orts Julien¹^ORCID,Kirchmair Johannes¹^ORCID,Rabenau Holger F.³,Rollinger Judith M.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria

2. Vienna Doctoral School of Pharmaceutical, Nutritional and Sport Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria

3. Institute of Medical Virology, University Hospital Frankfurt, Paul-Ehrlich-Straße 40, 60596 Frankfurt am Main, Germany

4. Swiss Federal Institute of Technology, Laboratory of Physical Chemistry, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland

5. Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, 1205 Geneva, Switzerland

6. Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1205 Geneva, Switzerland

Funder

Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung

Austrian Science Fund

Swiss Cancer Research Foundation

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Analytical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jnatprod.2c00843

Reference65 articles.

1. World Health Organisation. WHO Coronavirus (COVID-19) Dashboard https://covid19.who.int/ (accessed August 18, 2022).

2. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017

3. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron

4. Perspectives on SARS-CoV-2 Main Protease Inhibitors

5. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biopharmaceutical profiling of anti-infective sanggenons from Morus alba root bark for inhalation administration;International Journal of Pharmaceutics: X;2024-12

2. How many organic small molecules might be used to treat COVID-19? From natural products to synthetic agents;European Journal of Medicinal Chemistry;2024-11

3. Antiviral miliusanes and isolation of an unprecedented miliusane dimer from Miliusa balansae;Fitoterapia;2024-09

4. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective;Gene;2024-09

5. Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M^pro);ACS Omega;2024-08-02